LX-086 / Luoxin Pharma - LARVOL DELTA

[VIRTUAL] Preclinical evaluation of LX-086, a small molecule as a selective inhibitor of PI3K. (ASCO 2020) - "The selectivity of LX-086 in PI3Kα over PI3Kβ/δ/γ is similar with that of alpelisib, which had been approved by FDA in 2019. We have identified a novel potent and safe PI3Kα inhibitor LX-086. Preclinical studies show antitumor efficacy of LX-086 in PIK3CA mutant and amplified solid cancer models. LX-086 represents a promising clinical candidate for the treatment of solid cancers with PIK3CA mutation or amplification."

Preclinical • Breast Cancer • Gynecologic Cancers • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2 • PIK3CA